Endpoint Health, Inc., a Palo Alto, Calif.-based Precision-FirstTM therapeutics company dedicated to addressing unmet needs in immune-mediated acute and chronic diseases, closed a $52m equity and debt financing.
Major institutional investors participating in the Series A round included Mayfield, Humboldt Fund, AME Cloud Ventures, Boom Capital, Alix Ventures, Yaya Capital, Wireframe Ventures, The Venture Collective, HCX Ventures and Global Health Investment Corporation (GHIC).
Proceeds from the financing round will be used to extend the company’s Precision-FirstTM platform and expand its therapeutic pipeline to include programs for chronic immune-mediated diseases. In addition, proceeds will be used to advance Antithrombin III, Endpoint Health’s first precision therapy, to a Phase II clinical trial for the treatment of sepsis. The company expects to submit its Investigational New Drug (IND) application and Investigational Device Exemption (IDE) to the US Food and Drug Administration (FDA) for its Antithrombin III program later this year.
Led by Jason Springs, co-founder and Chief Executive Officer, Endpoint Health is a Precision-FirstTM therapeutics company dedicated to addressing unmet needs in immune-mediated acute and chronic diseases. We combine therapeutics, therapy-guiding tests, and AI to develop precision therapies for patients with immune-mediated conditions, such as acute respiratory distress syndrome (ARDS), sepsis, rheumatic and gastroenterologic diseases.
Completion of the Series A financing follows Endpoint Health’s recent announcement of a global collaboration and licensing agreement with Grifols to develop and commercialize Antithrombin III in sepsis.